News
EscharEx has demonstrated a favorable safety profile and effective wound bed preparation in multiple Phase II trials. The therapy has shown the ability to remove non-viable tissue, promote ...
Years ago, during my "marketing and sales period", a nurse approached me during a break at a seminar to ask my advice about a patient and his wound. Instead of describing the patient and his ...
Hosted on MSN2mon
MediWound announces Phase III CIDS publication on NexoBrid“NexoBrid provides a rapid, non-surgical solution that effectively removes eschar while preserving healthy tissue, addressing the critical need to protect viable dermis and improve outcomes for ...
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating V ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results